News
While androgen receptor (AR) inhibitors have long been a cornerstone in the treatment of metastatic hormone-sensitive prostate cancer (mHSPC), the ARANOTE trial (NCT04736199) sets darolutamide (Nubeqa ...
Discover the latest breakthroughs in oncology, including pivotal FDA decisions, promising therapies, and new treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results